Summary

The IXth World Conference on Clinical Pharmacology and Therapeutics (CPT 2008) is fast approaching; it will be held in Québec City, Canada from July 27th to August 1st, 2008. CPT 2008 is organized by the Canadian Society for Clinical Pharmacology and the National Research Council of Canada under the auspices of the International Union of Basic and Clinical Pharmacology.

Abstracts can be submitted online at http://www.cpt2008.org/e_call/call_e.shtml until February 1st, 2008. Notice of acceptance will be sent by March 31st, 2008. Accepted abstracts will be presented at poster sessions that will take place each day with viewing times during lunch and coffee breaks.

A stellar program has been put together by Dr. Patrick du Souich and his Scientific Program Committee. There will be two Plenary Sessions per day presented by distinguished and experienced speakers. The 39 oral symposia will feature outstanding speakers from around the world. Topics will include: New Insights in Treatment of Pain, Drug Transport and Metabolism in the Brain, Towards Quality Use of Medicines, Traditional Chinese Medicine, Pharmacogenetic Epidemiology, Pharmacovigilance, Geriatric Pharmacology, Prevention of Left Ventricular Hypertrophy and Cardiac Remodelling, Pediatric Pharmacology, and more. In addition, there will be a series of industry-sponsored symposia each day from 18:00 to 20:00. An exhibition, including displays by commercial and non-profit organizations, with companies showcasing innovative products and services, will be an integral part of the meeting.

CPT08 includes the 5th Canadian Therapeutics Congress (Canadian Society for Clinical Pharmacology, Canadian Association for Population Therapeutics, Canadian College of Clinical Pharmacy). A number of satellite symposia will be held in Québec City or in nearby centres just before or right after CPT 2008.

CPT 2008 will also include exciting social activities. Participants will not want to miss the Opening Ceremony featuring Inuit throat-singing, Huronne-Wendat dancing, and a unique show of forces (!) between French and English. Another event not to be missed is Fun Night on Thursday, August 31st; it will be a colourful evening combining food, refreshments and a circus performance in the tradition of Cirque du Soleil.

Québec City will be celebrating its 400th anniversary in 2008 with a series of events offering a daring touch of imagination and charm. Participants at CPT 2008 will also want to explore the province of Québec, known for its Joie de Vivre, or to visit other destinations in Canada.

The meeting website is active and it is already possible to make hotel reservations: see http://www.cpt2008.org/e_accomo/accommodation_e.shtml. It is recommended that participants book early because the 400th anniversary of Québec City is expected to attract many tourists.

The Early Registration Deadline is April 30 2008. Registrants before that date will benefit from a reduced registration fee. It is already possible to register on-line at http://www.cpt2008.org/e_regist/registration_e.shtml. A limited number of partial travel grants will be offered to young scientists from low and middle income countries.

To learn more about CPT 2008, please visit the Conference website at www.cpt2008.org or contact the Conference Secretariat at cpt2008@nrc-cnrc.gc.ca

We look forward to welcoming you at CPT 2008 in Québec City next summer!

For more information visit: http://www.cpt2008.org/e_mainmenu/welcome_e.shtml

Summary

Patient recruitment, enrollment and retention continue to be the most critical aspects of drug development and running successful clinical trials. Ideally, throughout their duration, clinical trials would have no enrollment or retention variation, but because this occurs regularly it is critical for sponsors to examine the key decision criteria to limit these changes.

Tools for Meeting Patient Recruitment Goals will provide presentations and interactive learning sessions that will explore the key decision criteria needed for successful patient recruitment planning. As well as hearing about successful practices from industry leaders, participants will have an opportunity to ask questions to experts -- in an informal environment that encourages open discussion.

I hope you will be able to join us for this one-of-a-kind event, as well as meet fellow attendees and speakers at an outing to the Orioles game the Sunday preceding the conference!

For more information visit: http://www.exlpharma.com/eventDetail.php?id=121

Summary

Nanotechnology has the potential to revolutionize medical treatments and medical practice. With hundreds of nanodrugs in development globally, the opportunities for clinical and market successes are apparent. Nanodrugs are at the forefront of bioengineering for diseases such as cancer, cardiovascular disease, and age-related conditions and represent the next generation of medical therapies that will impact worldwide markets, healthcare, and industry.

Arrowhead-Spectra's 1st International Conference on NanoDrugs and Clinical NanoTechnology provides an unmissable forum to learn the challenges and advances of pioneers in nanodrug development and be updated on the nanotechnologies applied to medical therapies. Case studies of pipelines, progress and clinical efficacy, and challenges of bioengineering and manufacturing will be the main themes of the conference.

The two-day expert-led event includes an Intellectual Property Workshop, a Masterclass, and presentations from leading international companies and institutes researching and developing nanomedicines.

For more information visit: http://www.spectraintelligence.com/nanodrugs.htm

Summary

* The Pharma CI Conference is widely attended by a large variety of executives from large, medium-sized, and  smaller pharmaceutical and biotechnology companies. This conference is the industry standard for professionals  in the pharma CI community. 

 * You will be provided with real insights, deep discussions, fresh     ideas and validating your corporate strategies in energizing  forums. 
    
 * You will gain knowledge and understand how industry changes are effecting and will continue to effect the way  you look at and position your brand, your next launch, your detailing, your pipeline, your sales force, your  own position within your company and the impact it has on your competition. 

For more information visit: http://www.pharmaciconference.com

Summary

In the current uncertain financial climate, with rising costs and tightening budgets, it is becoming more important than ever to minimize needless spending in clinical trials. Each day that a trial is carried out, sponsors incur enormous direct costs as well as significant expenses associated with lost sales opportunities. Further, with many top seller drugs coming off patent in the near future, increased competition from cheaper generics will add to the financial pressures that pharma companies continue to face. Although many costs are required to ensure safe and effective clinical trials, great potential exists for cutting unnecessary expenses while
maintaining, or even increasing, quality. While costs are on everyone's minds, many sponsors lack the practical tools to effectively decrease spending.

ExL Pharma's Clinical Cost Containment conference provides concrete information and strategies for reducing expenses while still achieving sound, high quality and meaningful clinical trials.  Case studies and best practices allow conference participants to learn what other leading and successful companies are doing to minimize costs.  Attendees will leave this conference with essential knowledge and skills to apply to their own divisions and take steps, both large and small, to maximize cost effectiveness when planning and executing clinical trials. 

For more information visit: http://www.exlpharma.com/eventDetail.php?id=123

Summary

Successful pharmaceutical companies understand how to build an optimal mix of innovative projects within a portfolio, bring them forward quickly and manage them effectively.

Are you able to sustain a balanced and growing portfolio? How can effective project management lead to the fastest time to market?

The increased pressures on the pharmaceutical industry, including shrinking pipelines and rising costs of bringing drug to market, intensifies the need for a good portfolio analysis. Reveal how to drive R&D project performance and minimize the risks in your portfolio.

This event will bring together the experts from the pharmaceutical industry to benchmark their best practices in executing effective project & portfolio management.

For more information visit: http://www.jacobfleming.com/conferences/life-science/4th-annual-project-&-portfolio-manage

Summary

The 2^nd annual World Drug Safety Congress brings together top pharmaceutical, biotechnology and regulatory representatives in a forum that addresses the key issues of the industry. The in-depth programme covers the detection, analysis and prevention of adverse drug reactions with case studies and industry experiences as well as global regulatory coverage of developments in the US, Japan, Europe, Asia/Pacific, South America and Canada.

The meeting is set to bridge the gap between international regulatory bodies, industry professionals and academic representatives and address how to drive pharmacovigilance operations forward into the 21^st Century.

For more information visit: http://www.terrapinn.com/2008/safety

Summary

This Jacob Fleming conference will provide solutions to some of the on-going challenges to Pharma L&D by looking at some of the best practices in the industry. Learning experts will provide honest and unbiased insights into how they have optimized their learning & training methods and techniques to achieve the desired blend between e-learning solutions and face-to-face learning.

 

For more information visit: http://www.jacobfleming.com/conferences/life-science/pharma-learning-development-2008

Summary

Following on from the huge success of the Exploratory Clinical Development World Europe

the congress will give you a critical insight into the latest strategies on how the industry is addressing and elevating the current challenges in early clinical development.

Exploratory Clinical Development World Americas you will gain the opportunity to hear about some of the scientific techniques being used to modernise drug development and to address the bottlenecks in early clinical development including computer models and simulation to predict device failures, qualified biomarkers, and innovative study designs.

For more information visit: http://www.healthnetworkcommunications.com

Summary

With Big Pharma increasingly reliant on biotechnology for its product pipeline and with biotech drugs now accounting for 15% of the global pharmaceutical market, the importance of biotechnology inventions and their patents is more important than ever. But the unique nature of biotechnology patents, the intense scrutiny involved with obtaining biotech patents and with patent standards constantly in flux, means that lawyers involved in obtaining and protecting patents in this high stakes arena, must have up-to-the-minute information.

C5 has specifically developed the 15th Annual Forum on Biotech Patenting to provide you with complete and in-depth information on current legal developments impacting your biotech patent practice. This the event that biotech patent lawyers attend year on year to get updates on the changes shaping biotech patents today, including recent scientific advances, developments in US patent practice, current discussion on the novelty of biotech inventions and further therapeutic use in Europe, EPC 2000, the growth of biologics, emerging case law and what is happening with biosimilars legislation.

The expert panel of regulators, in house counsel and their legal and other advisors, will provide you with
the key information and insights you need now on:
•    How the EPC 2000 will affect medical use claims and other areas of patent practice
•    How the growth of biologics in the newly approved medicines space is increasing the potential for litigation
•    Case law developments including re Kubin, Monsanto, KSR, Medimmune, Aeomica and more
•    What can you expect from government initiatives and what will be influencing the EPO, UKPTO and USPTO in the coming year?

New for 2008:
•    Keynote judicial address by Judge Randall Radar
•    Interactive case studies to gain insight into corporate perspectives on biotech patent litigation and patent entitlement disputes
•    Two pre-conference workshops designed to add value to your conference experience
•    Networking opportunities to help you create new industry contacts
•    Patent examiner’s insights on what biotech patent examiners really look for at the EPO


For more information visit: http://www.C5-online.com/BiotechPatenting

Summary

As Research and Development budgets continue to shrink for Pharmaceutical, Biotechnology and Medical Device companies, the need for effective communication between Sponsors and Sites has taken on increased importance as a means of cutting costs. This conference will bring together industry leaders to present unique approaches that these leaders have successfully implemented in their own companies.

Special attention will be paid to the biotechnology sector, a burgeoning area for many Pharmaceutical companies. In taking advantage of the shared experiences of companies that have long focused on biotech re search, traditional Pharma companies will enjoy a shortened road to financial viability as they continue to
expand into the biopharmaceutical arena.

ExL Pharma is adopting a more interactive format in response to a need echoed throughout the Pharmaceutical Industry to create a forum in which sites and sponsors may collaborate to align expectations and goals in every aspect of the drug development process.

For more information visit: http://www.exlpharma.com/eventDetail.php?id=126

Summary

Investigator initiated trials present regulatory, operational and financial
complexities to the pharmaceutical community.  Ever since the early-stages
of this important industry trend, ExL Pharma has brought the industry
together to address the important IIT topics, provide key speakers and host
networking opportunities that ensure that attendees come away with valuable
information, resources and new contacts to stay ahead of this curve and
succeed.

ExL Pharma now presents its 8th Successful, Compliant Investigator-Initiated
Trial Programs on September 25-26, 2008 at the Hyatt Regency in Newport
Beach California. In addition to fresh topics and new speakers, ExL is proud
to host the 2008 fall meeting for IISRA, the new IIT association formed by
your peers.  This fast-growing association is formulating its initial goals
to address the IIT challenges shared amongst the entire pharmaceutical
industry.  ExL Pharma is proud to play a supporting role towards the growth
of IISRA and to congregate the pharmaceutical, biotech and medical device
communities towards accomplishing shared goals.

                  
                    

For more information visit: http://www.exlpharma.com/eventDetail.php?id=124

Summary

This Jacob Fleming event features a two-day educational session with case studies, presentations and interactive sessions. Clinical Outsourcing Partnerships only invites the decision makers within the industry and provides an exclusive, business-driven environment. The event features prescheduled one-to-one business meetings and educational sessions that are strictly limited to upper-level executives.

You can benefit from:

Formal and informal networking sessions strategically designed for b2b sales
Pre-scheduled one to one business meetings
Keynote addresses and panel discussion by industry experts
Heavy marketing and branding

For more information visit: http://www.clinicaloutsourcingbcm.com?partner=RB

Summary

Pharma IQs Therapeutic Antibodies conference is the most commercially relevant of its kind and will examine effective strategies employed by both biotechnology and pharmaceutical companies. Discussions will cover the advantages and limitations of antibody-based products as well as patent issues and applicability.

Attendees will have the opportunity to hear from a selection of expert speakers on a range of topics at the top of the industry agenda and gain further perspective on common problems during discussions with peers.

For more information visit: http://www.iqpc.com/UK/antibodies

Summary

Presently, the market for pharmaceuticals designed to treat pain is worth over $30 billion. The dynamics of the global pain market have been altered greatly over the past few years. The decline of the multi-billion dollar Cox-2 class has created a void in the marketplace, as well as difficulties for companies wishing to launch new drugs in the class. The Cox-2 crisis has consequently increased opportunities for alternative pain therapies.

Arrowhead’s Second Annual Pain Therapeutics Summit is being organized to provide an integral forum for a critical examination of and discussion of the trends and issues facing the field of pain therapeutics.

This conference will provide you with thoughful insight from key industry leaders concerning cutting edge drug discovery science and preclinical development trends as well as analysis of key clinical-stage pain therapies and newly marketed products.

For more information visit: http://www.arrowheadpublishers.com/conferences/paintherapeutics2008/

Summary

Biopharmaceutical labs have many obstacles to overcome in developing, validating, maintaining, and transferring complex cell based assays in a quality control environment.  Whether you are new to developing and characterizing bioassays or you have several years of experience, you will benefit from discussing your current challenges with industry colleagues. The Cell Based Assays conference has become the meeting place for these scientists to discuss fresh information on how they are approaching solutions to these difficult assays.

Regulatory considerations, drug characterization, potency assays, setting acceptance criteria, neutralization antibodies assays, technological advancements, and statistical analysis are only some of the discussion topics. The format for learning is a combination of case studies and interactive panel discussions to address your most pressing assay challenges.

For more information visit: http://www.iirusa.com/cba/welcome-to-cell-based-assays.xml

Summary

From Basic Principles to Practical Solutions

---

Strengthen your comprehension of molecular interactions.
Bring back new applications to incorporate immediately.
Advance your candidates ahead with fewer unknowns.

Aid Drug Discovery & Development with Molecular Interaction Information

• Understanding molecular interactions and their applications in drug discovery & development
• Practical strategies for obtaining meaningful data on biomolecular interactions
• Linking in vitro affinity and kinetics to in vivo activity
• Alternative technologies for evaluating molecular interactions

Develop Analytical Tools for Measuring Monoclonal Antibody Therapeutics

• PK Assay strategies to support non-clinical and clinical studies
• Pharmacological and toxicological perspectives about which drug species should be measured
• Choosing a PK assay format: circulating target considerations
• Methods for measuring unbound therapeutic and “total” drug

New Emerging Strategies for Antibody-Drug Conjugates (ADCs)

• ADCs in preclinical and clinical development
• Unique challenges for ADC development
• Tools and current bioanalytical strategies
• Novel bioanalytical strategies

Gain New Insights of Fc Functionality

• Methods for in vitro assessment of Fc effector functionality
• Relate in vitro analyses to in vivo efficacy and toxicity
• Current state of Fc biology and Interaction of human IgG-Fc with FcyR
• Regulatory perspectives

For more information visit: http://www.iirusa.com/bamd/event-home.xml

Summary

Patient recruitment and retention in clinical trials is the leading bottleneck in the new drug development pipeline.

As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials.

Achieving success in this environment requires trial sponsors to play a larger role in the recruitment process and to develop more collaborative working relationships with all stakeholders, including investigators and patients.

For more information visit: http://www.jacobfleming.com/conferences/life-science/4th-patient-recruitment-and-retention

Summary

Following a phenomenally successful launch in Europe, Health Network would like to announce the forthcoming Clinical Outsourcing World Americas. This exciting three day conference is an essential port of call for you to hear the most recent industry developments and find solutions to the clinical outsourcing challenges that you face on a day to day basis. This event provides a forum in which industry leading pharmaceutical, biotechnology, academic and CRO representatives can identify the best practice in clinical outsourcing and learn more about sourcing factors, available partnership models, globalization of clinical trials, contractual and legal matters as well as relationship management techniques.

For more information visit: http://www.healthnetworkcommunications.com

Summary

Advancements in stem cell research and tissue engineering hold the promise of a new trove of regenerative therapies to treat diseases and conditions by restoring or repairing genetic and cellular defects. Over the past decade alone billions of dollars of investment have poured into the sector, and with over 550 global companies developing or collaborating on regenerative products, the clinical development stakes are high. Understanding the current challenges and the technological advances is critical for successful transition from bench to clinic.

Arrowhead-Spectra's 1st International Clinical Development Congress on Cell Therapies and Tissue Engineering is the forum to decipher the progress of clinical-phase candidates and technologies that have the potential to succeed in the highly competitive global marketplace. Based on presentations of case studies, trials, and proprietary data, the conference will be an unmissable event that focuses pioneering clinical development work.

For more information visit: http://www.spectraintelligence.com/regen.htm

Summary

What’s Big in 2008?

1. The China pharma market has emerged as one of the top markets for global drug sales. It is predicted that China will become the world’s largest pharmaceutical market by 2020, with sales topping $60 billion by 2010.

2. Pharmaceutical companies are grappling with the complexity of getting their drugs to the market, seeking effective collaboration with distributors and partners.

3. In the meantime, China healthcare reform in 2008 has significant impact on the pharma industry, creating new channels for distribution via CHCs.

This conference will provide a practical overview of China pharma and medical devices markets, equipping you with the know-how to operate more effectively and to exploit growth opportunities

For more information visit: http://www.ibcchina.com.cn/ibcchina/marlin/system/render.jsp?siteid=30000001182&marketingi